tetano
Editor, Senior Moderator
Ocul Immunol Inflamm
. 2023 May 5;1-8.
doi: 10.1080/09273948.2023.2200858. Online ahead of print. COVID Vaccine-Associated Uveitis
Zohar Habot-Wilner[SUP] 1 [/SUP], Piergiorgio Neri[SUP] 2 3 4 [/SUP], Annabelle A Okada[SUP] 5 [/SUP], Rupesh Agrawal[SUP] 6 7 8 9 [/SUP], Ng Xin Le[SUP] 6 [/SUP], Shai Cohen[SUP] 1 [/SUP], Naomi Fischer[SUP] 10 11 [/SUP], Fionn Kilmartin[SUP] 12 [/SUP], Amy Coman[SUP] 12 13 [/SUP], Dara Kilmartin[SUP] 12 13 [/SUP]
Affiliations
Purpose: Following the pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, different vaccines were developed and approved by the main medical authorities under emergency protocol regulations. Although highly effective and well-tolerated in most patients, vaccines can uncommonly cause ocular adverse effects. In this article, the current evidence related to vaccine-associated uveitis is reviewed.
Methods: A literature review of uveitis post various SARS-CoV-2 vaccinations.
Results: Uveitis was reported following various forms of vaccinations but was more commonly seen following the Pfizer mRNA vaccine which is the most used vaccination worldwide. In western countries, the most common uveitis is mild anterior uveitis, developing within a week of first or subsequent vaccination with good resolution following appropriate topical steroid therapy in most cases. Posterior uveitis and particularly Vogt-Koyanagi-Harada disease was more prevalent in Asia. Uveitis may develop among known uveitis patients and those with other autoimmune diseases.
Conclusion: Uveitis following Covid vaccinations is uncommon and has a good prognosis.
Keywords: COVID vaccination; SARS-Cov-2 vaccine-associated uveitis; SARS-Cov-2 vaccines; mRNA COVID vaccine; uveitis.
. 2023 May 5;1-8.
doi: 10.1080/09273948.2023.2200858. Online ahead of print. COVID Vaccine-Associated Uveitis
Zohar Habot-Wilner[SUP] 1 [/SUP], Piergiorgio Neri[SUP] 2 3 4 [/SUP], Annabelle A Okada[SUP] 5 [/SUP], Rupesh Agrawal[SUP] 6 7 8 9 [/SUP], Ng Xin Le[SUP] 6 [/SUP], Shai Cohen[SUP] 1 [/SUP], Naomi Fischer[SUP] 10 11 [/SUP], Fionn Kilmartin[SUP] 12 [/SUP], Amy Coman[SUP] 12 13 [/SUP], Dara Kilmartin[SUP] 12 13 [/SUP]
Affiliations
- PMID: 37145198
- DOI: 10.1080/09273948.2023.2200858
Purpose: Following the pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, different vaccines were developed and approved by the main medical authorities under emergency protocol regulations. Although highly effective and well-tolerated in most patients, vaccines can uncommonly cause ocular adverse effects. In this article, the current evidence related to vaccine-associated uveitis is reviewed.
Methods: A literature review of uveitis post various SARS-CoV-2 vaccinations.
Results: Uveitis was reported following various forms of vaccinations but was more commonly seen following the Pfizer mRNA vaccine which is the most used vaccination worldwide. In western countries, the most common uveitis is mild anterior uveitis, developing within a week of first or subsequent vaccination with good resolution following appropriate topical steroid therapy in most cases. Posterior uveitis and particularly Vogt-Koyanagi-Harada disease was more prevalent in Asia. Uveitis may develop among known uveitis patients and those with other autoimmune diseases.
Conclusion: Uveitis following Covid vaccinations is uncommon and has a good prognosis.
Keywords: COVID vaccination; SARS-Cov-2 vaccine-associated uveitis; SARS-Cov-2 vaccines; mRNA COVID vaccine; uveitis.